Life Seal Vascular wins $1.25M NSF grant for Cygnum device

Life Seal Vascular received a $1.25 million NSF SBIR Phase II grant to advance its Cygnum aneurysm sac management device toward FDA clinical trials. The non-dilutive funding is meant to support preclinical and pre-IDE work as the company moves closer to an IDE submission.

Why it matters: - The $1.25 million grant gives Life Seal Vascular non-dilutive capital for development work ahead of commercialization. - The funding supports a device aimed at endoleaks, a major failure point in endovascular abdominal aortic aneurysm repair. - The award could speed the path to FDA clinical trials for a product the company wants to position as a new vascular device category.

What happened: - Life Seal Vascular, a medical technology company based in Irvine, California, received a $1.25 million Phase II Small Business Innovation Research grant from the U.S. National Science Foundation on Aug. 6, 2026. - The award will support preclinical development and pre-Investigational Device Exemption activities for the Cygnum Aneurysm Sac Management Device, also called ASMD. - The company said the funding will help advance its regulatory pathway toward an FDA IDE clinical trial submission and approval.

The details: - The NSF grant is non-dilutive, which means the company does not have to give up equity to receive the money. - Life Seal Vascular said the award will help fund its research and engineering pipeline. - The Cygnum device is used as an adjunct to conventional endografts. - The device is designed to target endoleaks, which the company described as a multi-billion-dollar clinical failure point in EVAR. - The Cygnum ASMD recently completed a first-in-human trial with what the company described as excellent results. - The grant is supported under NSF Award No. 2537986. - America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses. - The program can provide up to $2 million for research and development support. - The NSF is an independent federal agency with a budget of about $8.5 billion. - Life Seal Vascular said its sealing technologies are designed to manage the aneurysm sac and improve the safety, durability and clinical effectiveness of EVAR. - More information is available on Life Seal Vascular's website. - More information about the federal program is available at America’s Seed Fund. - The company’s LinkedIn page is available at Life Seal Vascular on LinkedIn.

Between the lines: - The NSF award is a credibility signal as well as a financing event. - Federal backing can help de-risk a medtech startup in the eyes of investors, partners and regulators. - Life Seal Vascular is framing Cygnum as a platform that could create a new product category, not just a single device. - The company’s emphasis on non-dilutive funding suggests it is trying to preserve ownership while moving through costly regulatory steps.

What's next: - Life Seal Vascular will use the grant to continue preclinical and pre-IDE work. - The company is aiming for an FDA IDE clinical trial submission. - Further regulatory and development milestones will determine how quickly Cygnum advances toward broader commercialization.

The bottom line: - Life Seal Vascular now has federal funding and momentum behind a device designed to address one of EVAR’s biggest unresolved problems.